Whole-body Effective Half-life of Radioiodine in Children and Young Adults with Papillary Thyroid Cancer

Overview

Journal Endocrine

Date 2025 Feb 2

PMID 39893603

Authors

Yizhuo Wei

Wei Zhang

Taipeng Du

Yu Wang

Bin Liu

Affiliations

Soon will be listed here.

Abstract

Purpose: The lack of radioiodine-131 (RAI) kinetic study is a serious challenge for rational dosing for children and young adults (CYAs) with papillary thyroid cancer (PTC). The present study was conducted to investigate the whole-body effective half-life (EHL) and absorbed dose in RAI ablative therapy of CYAs with PTC.

Methods: In the period 2017-2022, all consecutive PTC patients 20 years or younger prepared for ablative RAI therapy after thyroid hormone withdrawal were prospectively recruited. Serial whole-body dose-rate measurements after administration were performed to deduce whole-body RAI retention. Calculations based on the deduced whole-body retention and the schema of Medical Internal Radiation Dosimetry were derived to determine whole-body EHL and absorbed doses. A multivariate linear regression analysis was employed to assess the association between whole-body EHL and potential predictors.

Results: A total of 52 patients (median age 17 years [range, 6-20 years]) were recruited. The mean whole-body EHL (±SD) was 10.3 (3.3) hours (median, 9.4 h [range, 6.3-21.7 h]). In univariable linear regression analysis, whole-body EHL was significantly associated with gender, body surface area (BSA) and body mass index (p < 0.05). Creatinine, Cystatin C, glomerular filtration rate (GFR) and positive post-ablation scintigraphy approached significance with respect to EHL (p ≤ 0.2 and ≥0.05). At multivariable analysis, BSA, GFR and positive post-ablation scintigraphy was associated with EHL. A median activity of 3.7 GBq of RAI (range, 1.85-7.40 GBq) was administered and a median whole-body absorbed dose of 0.22 Gy was delivered (range, 0.11-0.79 Gy).

Conclusion: A wide variation of whole-body EHL was observed in CYAs with PTC treated with RAI. The whole-body EHL is significantly longer in CYAs with larger BSA, decreased GFR and presence of extra-thyroidal disease. Understanding these predictors may improve our ability to dosing strategies in RAI therapy of CYAs with PTC.

References

Zhang X, Jiang L, Liu L, Liu B . Influence of body mass index at diagnosis on outcome of thyroid cancer in children and adolescents. Surgery. 2021; 169(6):1373-1378. DOI: 10.1016/j.surg.2020.12.047. View

Wei Y, Xiao L, Liu L, Shi L, Wang Y, Liu B . Prognostic implications of lymph node yield in pediatric patients with N1b papillary thyroid cancer. Oral Oncol. 2024; 158:106984. DOI: 10.1016/j.oraloncology.2024.106984. View

Xu Y, Shi L, Wu J, Li H, Wang Y, Liu B . Prognostic Value of Tumor Multifocality in Pediatric Papillary Thyroid Carcinoma: A Real-Life Multicentric Study. Otolaryngol Head Neck Surg. 2023; 169(6):1606-1614. DOI: 10.1002/ohn.373. View

Francis G, Waguespack S, Bauer A, Angelos P, Benvenga S, Cerutti J . Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2015; 25(7):716-59. PMC: 4854274. DOI: 10.1089/thy.2014.0460. View

Dinauer C, Francis G . Thyroid cancer in children. Endocrinol Metab Clin North Am. 2007; 36(3):779-806, vii. DOI: 10.1016/j.ecl.2007.04.002. View

Jarzab B, Handkiewicz-Junak D, Wloch J . Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review. Endocr Relat Cancer. 2005; 12(4):773-803. DOI: 10.1677/erc.1.00880. View

Hung W, Sarlis N . Current controversies in the management of pediatric patients with well-differentiated nonmedullary thyroid cancer: a review. Thyroid. 2002; 12(8):683-702. DOI: 10.1089/105072502760258668. View

Goldfarb M, Dinauer C . Differences in the management of thyroid nodules in children and adolescents as compared to adults. Curr Opin Endocrinol Diabetes Obes. 2022; 29(5):466-473. DOI: 10.1097/MED.0000000000000754. View

Taprogge J, Vergara-Gil A, Leek F, Abreu C, Vavrova L, Carnegie-Peake L . Normal organ dosimetry for thyroid cancer patients treated with radioiodine as part of the multi-centre multi-national Horizon 2020 MEDIRAD project. Eur J Nucl Med Mol Imaging. 2023; 50(11):3225-3234. PMC: 10256579. DOI: 10.1007/s00259-023-06295-0. View

10.

Salvatori M, Luster M . Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2010; 37(4):821-8. DOI: 10.1007/s00259-010-1398-0. View

11.

Jiang L, Xiang Y, Huang R, Tian R, Liu B . Clinical applications of single-photon emission computed tomography/computed tomography in post-ablation iodine scintigraphy in children and young adults with differentiated thyroid carcinoma. Pediatr Radiol. 2021; 51(9):1724-1731. DOI: 10.1007/s00247-021-05039-2. View

12.

Liu B, Peng W, Huang R, Tian R, Zeng Y, Kuang A . Thyroid cancer: radiation safety precautions in 131I therapy based on actual biokinetic measurements. Radiology. 2014; 273(1):211-9. DOI: 10.1148/radiol.14132234. View

13.

Buckley S, Chittenden S, Saran F, Meller S, Flux G . Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma. J Nucl Med. 2009; 50(9):1518-24. DOI: 10.2967/jnumed.109.064469. View

14.

Mosteller R . Simplified calculation of body-surface area. N Engl J Med. 1987; 317(17):1098. DOI: 10.1056/NEJM198710223171717. View

15.

Pottel H, Delanaye P, Schaeffner E, Dubourg L, Eriksen B, Melsom T . Estimating glomerular filtration rate for the full age spectrum from serum creatinine and cystatin C. Nephrol Dial Transplant. 2017; 32(3):497-507. PMC: 5837496. DOI: 10.1093/ndt/gfw425. View

16.

Jeon M, Kim Y, Sung T, Hong S, Cho Y, Kim T . Practical Initial Risk Stratification Based on Lymph Node Metastases in Pediatric and Adolescent Differentiated Thyroid Cancer. Thyroid. 2017; 28(2):193-200. DOI: 10.1089/thy.2017.0214. View

17.

Menzel C, Kranert W, Dobert N, Diehl M, Fietz T, Hamscho N . rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of (131)I. J Nucl Med. 2003; 44(7):1065-8. View

18.

Remy H, Borget I, Leboulleux S, Guilabert N, Lavielle F, Garsi J . 131I effective half-life and dosimetry in thyroid cancer patients. J Nucl Med. 2008; 49(9):1445-50. DOI: 10.2967/jnumed.108.052464. View

19.

Taieb D, Sebag F, Farman-Ara B, Portal T, Baumstarck-Barrau K, Fortanier C . Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal. J Clin Endocrinol Metab. 2010; 95(7):3283-90. DOI: 10.1210/jc.2009-2528. View

20.

Grenfell S, Roos D, Rijken J, Higgs B, Kirkwood I . Comparison of effective I-131 half-life between thyroid hormone withdrawal and recombinant human thyroid-stimulating hormone for thyroid cancer: a retrospective study. J Med Imaging Radiat Oncol. 2014; 59(2):248-54. DOI: 10.1111/1754-9485.12238. View